Immunovia IPO Takes Off, Fueled By Positive Early Results From Pancreatic Cancer Test
This article was originally published in Clinica
The largest pancreatic cancer diagnostic study to date shows Immunoniva’s IMMray PanCan-d test is 96% accurate in distinguishing stage I and II pancreatic cancer from healthy controls, the Lund, Sweden company announced Dec. 3.
You may also be interested in...
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
In this week’s podcast, Marion Webb reviews her interview with Glooko CEO Russ Johannesson and Reed Miller explains how Boston Scientific is restructuring its transcatheter aortic valve business.
The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.